Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptides, Reports Formulation Progress Across BPC-157, Retatrutide, and Others
核心洞察
Mountain Valley MD has completed initial Quicksome™ sublingual formulation work across multiple peptides including BPC-157, GHK-Cu (搜索), KPV (搜索), SNAP-8 (搜索), and retatrutide over the past six months.
The Quicksome™ platform is designed to convert injectable, refrigeration-dependent peptides into room-temperature-stable sublingual tablets, bypassing gastrointestinal degradation and first-pass metabolism.
The FDA's Pharmacy Compounding Advisory Committee will review seven peptides, including BPC-157 and KPV (搜索), for potential Category 1 reclassification at a meeting scheduled for July 23–24, 2026.
Mountain Valley MD Holdings Inc. (搜索) (MVMD) has reported significant progress in advancing its patented Quicksome™ sublingual delivery platform for compounded peptide applications, completing initial formulation work across several peptides of commercial significance including BPC-157, GHK-Cu (搜索), KPV (搜索), SNAP-8 (搜索), and retatrutide. The announcement, made today, positions the Company to capitalize on both the rapidly expanding peptide therapeutics market and a shifting U.S. regulatory landscape that may soon broaden compounding pharmacy access to multiple peptides currently restricted under FDA Category 2 classification.
Dennis Hancock, President and CEO of MVMD, framed the development as a strategic inflection point. "We believe the peptide category is entering one of the most important growth periods in its history," Hancock stated. "Our focus is entirely on Quicksome™ as a differentiated delivery platform that we believe has the potential to move important molecules from needle-based administration and refrigerated logistics toward a more accessible sublingual format."
The Bioavailability Challenge and Quicksome™ Technology
Peptide therapeutics face a fundamental delivery obstacle: peptide chains are highly susceptible to degradation by the acidic environment of the stomach and proteolytic enzymes of the gastrointestinal tract. Conventional oral formulations typically achieve negligible systemic bioavailability, making injection the dominant delivery method for most clinically active peptides. Sublingual delivery bypasses the gastrointestinal tract entirely, enabling absorption directly through the highly vascularized sublingual tissue into systemic circulation without first-pass degradation.
Quicksome™, MVMD's patented sublingual rapid-dissolve technology, formulates active molecules into a tablet that dissolves under the tongue. The Company believes this format may offer needle-free administration, potential elimination or reduction of refrigerated handling requirements, expanded distribution flexibility, and improved regimen compliance for needle-adverse patients.
The platform's cold chain credentials are supported by validation work conducted under a formal two-year collaborative research agreement with the FDA, announced in June 2021. In initial cold chain evaluations, Quicksome™ technology achieved 100% preservation and stability of IPV serotype two of a Trivalent Inactivated Poliovirus Vaccine after five days of exposure to 40 degrees Celsius, meeting the World Health Organization's Controlled Temperature Chain standard, which requires tolerance of 40 degrees Celsius for a minimum of three days. IPV serotypes one and three achieved 50% preservation in the same evaluation.
Regulatory Tailwinds in the Compounded Peptide Space
The U.S. regulatory framework surrounding compounded peptides is evolving in a direction that may materially expand the addressable market for differentiated delivery technologies. On February 27, 2026, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. publicly stated that approximately 14 peptides currently on the FDA's Category 2 Bulk Drug Substances List are expected to be considered for potential return to Category 1 status, which would permit licensed compounding pharmacies to prepare them under physician prescription.
On April 16, 2026, the FDA confirmed a Pharmacy Compounding Advisory Committee meeting scheduled for July 23 and 24, 2026, at which seven peptides will be reviewed for potential inclusion on the 503A Bulk Drug Substances List: BPC-157, TB-500, KPV (搜索), MOTS-c, Emideltide, Semax, and Epitalon. A second meeting anticipated before February 2027 will review five additional peptides including GHK-Cu (搜索), Melanotan II, Cathelicidin, Dihexa acetate, and PEG-MGF. A positive Committee recommendation initiates a formal rulemaking process, though the timing of any reclassification remains subject to that process.
"The regulatory environment appears to be moving toward a broader re-evaluation of compounded peptides, and we believe that creates a potentially important opening for differentiated delivery technologies," Hancock commented. "BPC-157 is on the FDA's formal review list. Retatrutide is one of the most closely watched pharmaceutical developments of this decade."
Market Context and Commercial Strategy
The global peptide therapeutics market was valued at approximately USD $141 billion in 2025 and is projected to reach approximately USD $295 billion by 2033, growing at an approximately 8.7% compound annual growth rate. Within this landscape, GLP-1 receptor agonists have emerged as a dominant commercial force: semaglutide and tirzepatide generated combined global reported revenues of approximately USD $46 billion in 2024. Retatrutide, Eli Lilly's triple agonist currently in Phase III clinical trials, is projected by industry analysts to generate revenues in the range of USD $15 billion to USD $30 billion by 2031.
MVMD does not own, develop, or hold any rights to GLP-class molecules or any of the underlying peptide molecules referenced. The Company's work is limited to evaluating the applicability of its Quicksome™ delivery platform to such molecules within the compounded pharmacy channel.
MVMD's commercialization strategy focuses on establishing Quicksome™ as a platform technology that may be licensed, integrated, or commercialized through compound pharmacy, telehealth, wellness, and broader bioactive molecule distribution relationships, rather than pursuing traditional pharmaceutical drug development pathways. Current activities include ongoing formulation refinement, dosing optimization work, stability assessment, compound pharmacy engagement discussions, and evaluation of regional commercialization structures across North and South America.
"Quicksome™ is a platform technology, not a single-product opportunity," said Hancock. "The commercial case is straightforward: if we can take molecules that currently require refrigeration and injection and reformulate them into a sublingual tablet that is stable at room temperature and can be taken without a needle, we change the distribution economics and the patient experience for that molecule entirely."
The Company expects its next phase of work to include continued formulation advancement, expanded business development discussions, and evaluation of potential pilot commercialization opportunities involving select Quicksome™ peptide applications where legally permissible and commercially appropriate.